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Objective.Tocorrelatevisualandneurologicclinicalscoresandtreatmentofopticneuritisandmultiplesclerosis(MS)patientswith
assays of serum phosphorylated neuroﬁlament heavy chain (pNF-H) and optical coherence tomography (OCT) measurements of
axonal loss. Design/Methods. The Optic Neuritis Treatment Trial (ONTT) randomized 457 patients with acute optic neuritis to
intravenous methylprednisolone (IVMP) followed by oral prednisone, oral prednisone or placebo treatment arms. We quantiﬁed
serum pNF-H levels in 175 ONTT patients 5 years after study entry. We performed OCT measurements of macular volume and
the retinal nerve ﬁber layer (RNFL) in a subset of 51 patients at year 15. Results. Elevated pNF-H levels at year 5 correlated to
poorer visual function at study entry. Lower 15 year macular volumes and RNFL thickness correlated better with follow-up than
with baseline visual function measures. With IVMP treatment, 15 year RNFL diﬀerences of the fellow eye (FE) minus the aﬀected
eye (SE) RNFLFEmSE correlated with ﬁve-year pNF-H levels. PNF-H was reduced by half with IVMP relative to placebo or by
40% relative to prednisone. Conclusions/Relevance. Acute optic neuritis patients who have more severe visual loss during initial
presentation have a higher incidence of axonal loss that was slightly suppressed with IVMP treatment.
1.Introduction
The Optic Neuritis Treatment Trial (ONTT) compared
three modes of treatment for acute unilateral optic neuritis:
placebo, oral prednisone, or high-dose IVMP followed by
oral prednisone [1]. Enrollment of 457 patients by 15 centers
started in 1988 and was completed 3 years later. Results of
the study showed that visual acuity recovered 2 weeks faster
with IVMP. Six months after treatment, no diﬀerence in the
generally good visual outcome was detected between the 3
treatment groups. Similarly, there were no diﬀerences in the
number of a minority of patients with a poor visual outcome
varying between 5% and 6% for each group and deﬁned by
the study as 20/50 or worse.
Axonal and neuronal loss are increasingly recognized
as the primary factors contributing to persistent deﬁcits
and disability in multiple sclerosis (MS) and optic neuritis
[2–4], as also revealed by optical coherence tomography
(OCT) [5, 6]. Neuroﬁlaments are components of the axonal
cytoskeleton that consists of several subunits, including a
light, medium, and heavy chain (NF-L, NF-M and NF-
H). They are released into the blood stream and CSF with
axonal disruption [7] that is believed to be mediated by
inﬂammatory cells in multiple sclerosis [8]. The heavily
phosphorylated axonal form of NF-H, called pNF-H, is
resistant to proteases and relatively easy to detect [9, 10].
Petzoldand coworkershave described elevatedlevels ofpNF-
H during the acute phase of visual loss from optic neuritis
[11–13]. NF-H levels correlated with poor visual recovery
and the development of MS. We wondered whether serum
pNF-H levels may be a useful gauge of axonal loss in a large
cohort of optic neuritis and MS patients.
2. Methods
2.1. Clinical Assessments. ONTT patients underwent visual
acuity, visual ﬁeld, and contrast sensitivity testing at study
entry then at the one-month, 6-month, 5-year, 10-year, and
15-year follow-up visits. EDSS assessments were performed
at the 5-year, 10-year, and 15-year follow-up examinations.2 Multiple Sclerosis International
MRI was performed at baseline and at the ﬁve-year examina-
tion [14–17].
2.2. pNF-H Assay. Serum derived from venous blood was
drawn during follow-up examinations 5 years after patient
enrollment into the treatment arm of the study. Serum was
stored in a −80 freezer for 10 years. Serum was assayed for
the presence of phosphorylated neuroﬁlament heavy chain
(pNF-H), using a recently described monoclonal antibody-
based assay [18] .W e l l so fm i c r o t i t r ep l a t e sw e r ec o a t e d
overnight with 100µL of puriﬁed pNF-H monoclonal cap-
ture antibody clone AH1, diluted in 10mL 0.05M carbonate
buﬀer, pH 9.5 to give a ﬁnal concentration of 1µgI g G
per ml. The antibody and carbonate mix was decanted and
the plates blocked with 150µLo f5 %n o n f a tm i l ki nT B S
for 1 hour. The plate was washed with 2% nonfat milk in
TBS and 0.1% Tween 20 (pH 7.5). After washing, a total
of 50µL of standard or 20µL serum sample plus 30µL2 %
nonfat milk in TBS and 0.1% Tween 20 were added in
duplicate to the plate. The plates are incubated on a shaker at
room temperature for 1h. After washing, 100µLo fp u r i ﬁ e d
mouse anti-pNF-H monoclonal antibody, directly coupled
to horse radish peroxidase (HRP) at a ﬁnal concentration
of 1µg/mL in 2% nonfat milk in TBS plus 0.1% Tween 20
were added to each well and the plate incubated for 1h at RT.
After a ﬁnal wash, the reaction was visualized using 100µL
per well of 3,3 ,5,5 -tetramethybenzidine HRP developer
solution (Thermo Fisher, Rockford, IL). Absorbance was
read at a wavelength of 450nm on a Tecan SpectraFluor
ELISA plate reader, 15 minutes after addition of chromogen,
and after stopping the reaction by the addition of 50µL
1M H2SO4 per well. The entire set of samples were run as
described twice with excellent reproducibility. The pNF-H
antibodies used here can be obtained commercially from
EnCor Biotechnology Inc. (Gainesville, FL).
2.3. OCT. Optical coherence tomography (OCT) [19, 20],
an indirect way of measuring retinal nerve ﬁber layer
thickness around the optic nerve, and macular volumes
were obtained in a subset of 51 patients, 10 years after
drawing blood samples (15 years after ONTT enrollment).
Peripapillary retinal nerve ﬁber layer (RNFL) thickness was
evaluated using the fast RNFL program of the Stratus
OCT (Carl Zeiss Meditec, Dublin, CA), and analyzed using
software version 3.0. RNFL thickness is determined at 256
points around a circular scan (diameter 3.4mm) around the
center of the optic disc that is repeated 3 consecutive times.
For each eye, RNFL scans were repeated 4 times, exported on
an electronic worksheet, and an average scan was computed.
RNFL thickness and macular volume were evaluated from
the average scan. OCT data from the clinical centers was
collected by the reading center at the University of Iowa.
2.4. Data Analysis. Pearson correlation analysis of data
was performed using SPSS statistical software (Chicago,
IL). The association of subject characteristics to pNF-H
levels was studied with multiple regression. The pNF-H
data were square root transformed to eﬀect normality of
Table 1: Baseline (recruitment) participant characteristics of
ONTT subjects undergoing pNF-H testing.
Number 175
Mean (SD) [range] age 33.2 (6.8) [18,46]
N (%) Female 140 (80%)
N (%) Race/Ethnicity
Caucasian 159 (91%)
African-American 15 (9%)
Hispanic 1 (1%)
N (%) Right eye aﬀected 92 (53%)
N (%) Initial multiple sclerosis
None 114 (65%)
Possible 35 (20%)
Probable 9 (5%)
Deﬁnite 17 (10%)
Treatment group
IVMP 63 (36%)
Prednisone 63 (36%)
Placebo 49 (28%)
distribution of residuals. Relationships between the square
root of pNF-H were investigated within groups with Pearson
correlation and the two-sample t-test. Linear regression was
used to assess the diﬀerence between groups and whether
the relationship was diﬀerent between clinically isolated
optic neuritis patients and those with clinically deﬁnite MS.
Analysis of covariance was used to assess the inﬂuence of
treatment on pNF-H levels.
3. Results
3.1. pNF-H and Treatment. We quantiﬁed pNF-H levels
in the serum of 175 (44%) of the 397 patients, 87% of
those initially entered into the ONTT, who returned for
follow-up examinations 5 years after enrollment into the
study. Their baseline characteristics are listed in Table 1.A
normal control group of age-matched volunteers free of any
neurologic diseases had a mean pNF-H concentration of
0.07 ± 0.05 nanograms (ng) per milliliter (mL) (mean ±
standard deviation) (n = 12). Sixty-three of the ONTT
patients had received IVMP, 63 patients had received oral
prednisone, and 49 patients had received oral placebo. Post
hoc least signiﬁcant diﬀerence tests revealed serum pNF-H
was reduced by 50% with IVMP with a value of 0.096 ±
0.692ng per mL relative to placebo with a mean of 0.192 ±
0.399ng per mL (diﬀerence = −0.067; P = .047) or by 40%
relative to prednisone with a mean of 0.145 ± 0.134ng per
mL (diﬀerence = −0.073, P = .021) (Figure 1(a)).
3.2. pNF-H and Clinical Parameters. Next, we investigated
whether the increases in pNF-H levels of placebo and
prednisone-treated patients relative to those who received
IVMP, shown by the study to reduce the risk of developing
MS for approximately 2 years [21], were due to optic neuritis
itself or the coexistence of MS. For this analysis, we separatedMultiple Sclerosis International 3
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Figure 1: Bar plots of pNF-H concentration (nanograms per mL) in optic neuritis patients by treatment group (a) and between optic
neuritis cases with or without MS at 5 years (b). Error bars = standard deviation.
treatment groups into those with clinically isolated optic
neuritis and those with multiple sclerosis (Figure 1(b)).
Among these 175 patients, 17 (10%) initially had clinically
deﬁnite multiple sclerosis (CDMS). During ONTT follow-
up, another 78 (46%) developed CDMS after an average
of 4.1 years. We found no signiﬁcant diﬀerence (P = .74,
ANOVA) in average pNF-H concentration between patients
with onset of CDMS at or prior to the year-ﬁve visit (mean
± SD = 0.16 ± 0.31), patients with CDMS after the ﬁve-
year visit (0.11 ± 0.11), or optic neuritis patients who never
developed CDMS (mean ± SD = 0.14 ± 0.16). Neither was
pNF-H concentration predictive of onset of CDMS after
ﬁve years among the 98 patients who had not previously
developed it (P = .51, Cox proportional hazards regression.
Risk Ratio = 0.86, 95% CI: 0.54, 1.36 for a 0.1 unit higher
concentration of pNF-H). Thus, reductions in pNF-H by
IVMP were not due to suppression of MS, but likely due to
suppression of axonal injury in the optic nerve.
Next, we compared baseline and 5-year measurements
by randomized treatment assignment and 15-year follow-
up with OCT (Table 2). For the subset of 51 patients that
had underwent OCTs during the year-15 visit we found that
higher pNF-H levels at year 5 correlated to poorer visual
acuity (P = .001), worse contrast sensitivity (P = .007),
and denser visual ﬁeld defects (P = .038) at the baseline
(BL) study entry visit. Figure 2(a) illustrates the increase in
serum pNF-H with worsening baseline visual acuity in the
aﬀected eyes with acute optic neuritis. Figure 2(b) shows
that higher pNF-H correlates with more severe visual ﬁeld
defects at baseline. Figure 2(c) shows higher serum pNF-H
that correlates with loss of contrast sensitivity at entry into
the ONTT. No correlations of visual function to pNF-H were
seen in any of the follow-up visits. No correlations of pNF-
Ht oE D S Ss c o r e so n l yd o n ea ty e a r5 ,y e a rt e n ,a n dy e a r
15 were detected. No correlations of pNF-H to MRI lesions
were detected. Table 3 shows the progression of MS EDSS
from year 5 to 15 for those diagnosed with MS at baseline,
6 months, 5 years, 10 years, or 15 years after study entry.
Interestingly,theincidenceofdiagnosedMSwassigniﬁcantly
lower in the cases that returned for the 15-year follow-up for
OCT (P = .012). We discuss their OCT ﬁndings next.
3.3. OCT. OCT signal strengths ranged from 5 to 10 in
both fellow and aﬀected eyes, with 44 (86%) and 47
(92%) having signal strength greater or equal to 7. Table 4
shows the RNFL and macular volumes by treatment group.
Diﬀerences between aﬀected eyes relative to the fellow eyes
were statistically signiﬁcant.
3.4. OCT and Clinical Parameters. We found a signiﬁcant
correlation of baseline visual acuity loss to a reduction
in total macular volume in the subset of 51 patients that
had their RNFL and macular volumes thickness measured
with Stratus OCT at the 15-year follow-up visit. Table 5
shows the OCT correlations to visual function and EDSS
for each visit alongside the pNF-H measurements. Macular
volume and RNFL loss correlated to a signiﬁcant loss of
visual acuity at the one-month follow-up visit. Contrast
sensitivity loss of aﬀected eyes (CSENAF) and denser visual4 Multiple Sclerosis International
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Table 3: MS characteristics.
Diagnosis of MS All
Baseline, N = 17 Month 6, N = 11 Year 5, N = 44 Year 10, N = 14 Year 15, N = 9 N = 95
Mean (SD) EDSS
Year 5 1.97 (1.59) 1.77 (1.82) 1.30 (0.98) 0.71 (1.09)∗ 0.22 (0.44)∗∗ 1.28 (1.29)
Year 10 2.79 (1.88) 1.96 (1.96) 2.42 (2.41) 2.35 (2.13) 0.78 (0.79)∗∗∗ 2.24 (2.14)
Year 15 3.83 (1.90) 2.55 (1.62) 2.94 (2.46) 2.96 (2.12) 1.33 (1.36) 2.84 (2.18)
Year 5 mean (SD) sqrt pNFH
IV 0.29 (0.04) 0.24 (0.11) 0.25 (0.11) 0.33 (0.09) 0.22 (0.05) 0.26 (0.09)
Prednisone 0.45 (0.13) 0.36 (0.20) 0.33 (0.16) 0.31 (0.07) 0.41 (0.36) 0.37 (0.17)
Placebo 0.20 (0.13) 0.21 (0.20) 0.46 (0.34) 0.30 (0.06) 0.34 (0.11) 0.36 (0.27)
P = .008 P = .52 P = .065 P = .85 P = .52 P = .041
≥5 MRI lesions at baseline 13 (77%) 3 (30%) 16 (42%) 4 (29%) 4 (57%) 40 (47%)
Year 15 mean (SD) RNFL N = 2 N = 3 N = 8 N = 3 N = 4 N = 20
Aﬀected eye 79.4 (4.6) 70.0 (8.1) 69.7 (19.8) 65.0 (17.0) 66.0 (25.5) 69.3 (17.4)
Fellow eye 94.6 (3.8) 74.2 (16.3) 82.0 (19.0) 97.3 (2.7) 73.1 (24.5) 82.6 (18.3)
Diﬀerence 15.2 (0.8) 4.2 (8.5) 12.4 (16.4) 32.3 (15.1) 7.1 (6.5) 13.3 (14.7)
Year 15 mean (SD) macular volume
Aﬀected eye 7.1 (0.9) 6.1 (0.7) 6.0 (0.5) 6.8 (0.5) 6.2 (0.6) 6.3 (0.6)
Fellow eye 7.6 (0.1) 6.2 (0.8) 6.6 (0.6) 7.3 (0.9) 6.7 (0.7) 6.7 (0.7)
Diﬀerence 0.5 (0.8) 0.1 (0.2) 0.6 (0.5) 0.5 (0.4) 0.2 (0.2) 0.4 (0.4)
Table 4: OCT data RNFL and macular volumes.
IVMP
N = 18
Placebo
N = 15
Prednisone
N = 18
Total
N = 51
Signal strength
Aﬀected eye 8.2 ± 1.2 8.2 ± 1.2 7.9 ± 1.5 8.1 ± 1.3
Fellow eye 8.1 ± 1.8 8.5 ± 1.1 8.4 ± 1.2 8.3 ± 1.4
Year 15 mean (SD) RNFL
Aﬀected eye 80.9 ± 18.1 71.3 ± 22.7 78.2 ± 17.1 77.1 ± 19.3
Fellow eye 95.2 ± 16.7 87.1 ± 18.1 94.5 ± 18.5 92.6 ± 17.8
Diﬀerence (AF-FE) −14.3 ± 17.3 −15.8 ± 22.4 −16.3 ± 15.9 −15.5 ± 18.2
P-value .003 .016 <.001 <.001
Year 15 mean (SD) macular volume
Aﬀected eye 6.3 ± 0.5 6.5 ± 0.7 6.4 ± 0.5 6.4 ± 0.6
Fellow eye 6.7 ± 0.5 6.9 ± 0.8 7.0 ± 0.6 6.9 ± 0.7
Diﬀerence −0.4 ± 0.5 −0.4 ± 0.5 −0.7 ± 0.6 −0.5 ± 0.6
P-value .005 .010 <.001 <.001
ﬁeld defects (MDSE) correlated to the OCT parameters of
axonal loss at almost every time point except the baseline
clinical examination.
Looking at the OCT ﬁndings by treatment group, we
found no signiﬁcant diﬀerence of mean IVMP RNFL =
81µm( n = 18), 78µm with prednisone (n = 18), or
71mm placebo (n = 15) (Figure 3(a)). RNFL measurements
of aﬀected and nonaﬀected eyes of patients with CDMS
(n = 20), respectively, 69µma n d8 2µm, were signiﬁcantly
diﬀerent (resp., P = .018 and P = .001) from those
with clinically isolated optic neuritis, respectively, 83µma n d
99µm( n = 31). The average ± SD RNFL thickness in all
aﬀected eyes of 77.1 ± 19.3µm was signiﬁcantly thinner than
the fellow eye (P<. 001, t-test) with an average 92.6 ±
17.8µm. These diﬀerences were also true for the macular
volumes.
Lastly,wefoundnostatisticalcorrelationofpNF-Hlevels
to recovery of visual acuity at 6 months or RNFL thickness
at 15 years in patients with or without MS. However, RNFL
thickness diﬀerences of fellow eye (FE) minus study eye
(SE) RNFLFEmSE correlated to pNF-H levels in the IV
methylprednisolone group (P = .04) (Figure 3(b)). Thus,
IVMP-treated patients with greater loss of axons at year 15
had increased pNF-H levels at year 5.6 Multiple Sclerosis International
Table 5: Correlations of clinical proﬁle to OCT and pNF-H.
Measurement Visit Statistic Study eye RNFL
thickness
Study eye total
macular volume
Square root
pNFH
EDSS
Year 5
r −0.28 −0.28 0.15
P-value .048 .057 .291
N 50 47 50
Year 10
r −0.38 −0.11 0.02
P-value .008 .473 .901
N 49 46 49
Year 15
r −0.23 0.07 0.03
P-value .107 .641 .841
N 51 48 51
LogMAR study eye acuity
Baseline
r −0.09 −0.29 0.44
P-value .512 .046 .001
N 51 48 51
Month 1
r −0.44 −0.41 0.13
P-value .002 .005 .364
N 48 45 48
Month 6
r −0.35 −0.22 −0.11
P-value .011 .132 .442
N 51 48 51
Year 5
r −0.27 −0.26 −0.18
P-value .060 .074 .206
N 51 48 51
Year 10
r −0.52 −0.30 −0.08
P-value <.001 .040 .565
N 50 47 50
Year 15
r −0.48 −0.36 0.00
P-value <.001 .011 .974
N 51 48 51
Sensitivity study eye contrast
Baseline
r 0.18 0.23 −0.37
P-value .207 .121 .007
N 51 48 51
Month 1
r 0.54 0.42 −0.17
P-value <.001 .004 .256
N 48 45 48
Month 6
r 0.54 0.44 −0.12
P-value <.001 .002 .419
N 51 48 51
Year 5
r 0.45 0.37 −0.04
P-value .001 .010 .759
N 50 47 50
Year 10
r 0.52 0.43 0.01
P-value <.001 .003 .964
N 49 46 49
Year 15
r 0.58 0.52 −0.06
P-value <.001 <.001 .685
N 51 48 51Multiple Sclerosis International 7
Table 5: Continued.
Measurement Visit Statistic Study eye RNFL
thickness
Study eye total
macular volume
Square root
pNFH
Study eye visual ﬁeld mean deviation
Baseline
r 0.24 0.30 −0.29
P-value .095 .036 .038
N 51 48 51
Month 1
r 0.56 0.46 −0.11
P-value <.001 .001 .462
N 48 45 48
Month 6
r 0.55 0.34 0.08
P-value <.001 .019 .593
N 51 48 51
Year 5
r 0.48 0.32 0.06
P-value <.001 .029 .650
N 51 48 51
Year 10
r 0.57 0.40 0.10
P-value <.001 .006 .512
N 50 47 50
Year 15
r 0.55 0.30 0.05
P-value <.001 .041 .730
N 51 48 51
4. Discussion
We have shown here that serum pNF-H levels measured 5
years after acute optic neuritis correlate with baseline visual
function. Next, early follow-up visual function correlates
with RNFL and macular volumes measured at 15 years.
Lastly,pNF-Hlevelsatyear5donotcorrelatewithRNFLand
macular volumes in the aﬀected eye, but they do correlate
with the diﬀerence between study and fellow eyes at least in
the IVMP group.
Our ﬁndings of increased pNF-H levels with more severe
baseline visual deﬁcits are consistent with axonal transection
byinﬂammatorycellsthatisbelievedtocontributetotheloss
of axons [8]. This insult occurs at baseline, and the axons
starttheprocessofdyingoﬀ,releasingpNF-Hintotheserum
as they do. This process of degeneration appears to continue
for at least 5 years. OCT measures what is remaining after
the axons have died oﬀ, thus a better correlation to the
follow-up exams. Teunissen et al. showed that neuroﬁlament
heavy chain levels detected in the CSF of patients with
MS and clinically isolated syndrome were higher than
normal controls, reaching their highest levels during acute
exacerbations of disease activity [22]. Petzold et al., who
obtained serum samples for measurements of the pNF-H
during the acute phases of optic neuritis, found higher levels
in those who had a poor visual recovery [12]. Since acute
serum samples from ONTT patients were unavailable for
inclusion in our study here, we had only a single snapshot of
pNF-H,atyear5.Therefore,weareunabletoresolvewhether
axonal transection by inﬂammatory cells was suppressed by
IVMP or whether treatment induced a decrease in release of
pNF-H. Still, due to its high resistance to protease digestion
[9], pNF-H may have persisted at higher levels for years,
though this seems unlikely. Alternately, a small amount of
axonal loss and regeneration may be an ongoing feature of
optic neuropathy, and IVMP may have a long-term eﬀect by
reducing this.
While we found no correlation of pNF-H to clinical
measures of visual function at the very late time points,
and pNF-H was not associated with study eye RNFL even
in the IVMP group, the diﬀerence between fellow eye and
studyeyeRNFLthicknesscorrelatedwithpNF-Hlevelsinthe
IVMP group. This ﬁnding validates pNF-H as a biomarker of
suppression of axonal loss by high-dose methylprednisolone,
nowstandardtherapyforacuteopticneuritisandMSexacer-
bations. Since no diﬀerence in serum pNF-H concentration
between clinically isolated optic neuritis and MS patients
were detected, it is unlikely that brain lesions outside the
optic nerve contributed to the diﬀerences in pNF-H between
the IV methylprednisolone and the other two treatment
groups. We also excluded brain lesions in clinically isolated
optic neuritis and multiple sclerosis patients detected on
T2-weighted MRI as a cause for the diﬀerences in pNF-H
between the treatment groups.8 Multiple Sclerosis International
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Figure 2: (a) A scatterplot shows the increasing pNF-H with
worseningbaselinevisualacuityintheaﬀected eyes with acute optic
neuritis.(b)ThescatterplotshowselevatedserumpNF-Hcorrelates
with poorer contrast sensitivity at entry into the ONTT. (c) A
scatterplot shows that higher pNF-H correlates with more severe
visual ﬁeld defects at baseline.
Consistent with our observations in ONTT patients,
elevation of serum pNF-H has also been found in another
disease that aﬀects the optic nerve, Lebers’ hereditary
optic neuropathy (LHON) [23]. Elevations in serum pNF-
H have also been detected in animals with experimental
autoimmune encephalomyelitis (EAE) and suppressed with
treatment [24]. As further veriﬁcation that axonal loss
from optic neuritis was the likely source of the pNF-H
in ONTT patients, we turned to transgenic TCR MOG
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Figure 3: (a) A barplot of OCT RNFL thickness at 15 years in
a subset of 51 patients shows no signiﬁcant diﬀerence of mean
RNFLwithtreatmentofopticneuritispatientswithMSorclinically
isolated optic neuritis patients without MS. (b) A scatterplot of
RNFLthicknessdiﬀerenceofthefelloweye(FE)minusthestudyeye
(SE) RNFLFEmSE correlated to serum pNF-H levels in the IVMP
group.
mice that develop only optic neuritis that in turn causes
loss of retinal ganglion cells and their optic nerve axons
[25]. Preliminary unpublished observations in these animals
revealed a several fold elevation in serum pNF-H levels
relative to control littermates (presented at the AAN Toronto
2010—[P06.229]). Thus, serum pNF-H elevations in ONTT
patients were likely due to optic neuritis, and this biomarker
is likely a reliable monitor for suppression of axonal injury in
the optic nerve.
DespitetheOCTandpNF-Hcorrelationdatasupporting
a long-term beneﬁt of treatment with IVMP, its eﬀect
on visual parameters and neurologic or MRI lesions was
virtually nil. For month 1, month 6, year 5, year 10, and year
15, treatment had very little aﬀect on outcome variables of
acuity, contrast sensitivity, visual ﬁeld mean deviation, EDSS
score, or MRI lesions [1]. Only contrast sensitivity at month
1 and month 6, and mean deviation at month 6 were, or
approached being, signiﬁcantly diﬀerent with IVMP. Thus,Multiple Sclerosis International 9
contrast sensitivity may be a sensitive clinical measure of
treatment outcome. In fact, using low contrast acuity as an
outcome measure, Balcer and colleagues demonstrated that
natalizumab treatment of MS patients was beneﬁcial to this
parameter of visual function only [26]. That study did not
examine the eﬀects of treatment on axonal or neuronal loss.
Corticosteroids have been shown to suppress axonal loss
in the optic nerves of animals with experimental autoim-
mune encephalomyelitis (EAE) [27]. On the other hand,
in this animal model of MS, corticosteroids have also been
shown to induce neuronal degeneration in retinal ganglion
cells whose axons comprise the optic nerve [28]. Thus,
corticosteroids appear to have opposing eﬀects on diﬀerent
elements of the visual system in animal experimental mod-
els. In optic neuritis associated with neuromyelitis optica
(NMO), IVMP treatment resulted in a better visual outcome
and suppressed RNFL loss [29]. In a study of MS, no
diﬀerences in RNFL were detected between patients treated
with interferon beta-1a, interferon beta-1b, or glatiramer
acetate relative to placebo [30]. To our knowledge, our
study is the ﬁrst demonstrating that an anti-inﬂammatory
pharmacologic agent is able to modulate a marker of axonal
loss in optic neuritis patients that do not have NMO. Since
axonal loss is a characteristic of optic neuritis that may
be slightly suppressed by methylprednisolone at a dose of
1gram a day for 3 days, one can only wonder whether
substantial escalation of the dose would have a greater
neuroprotective eﬀect than that seen here. Perhaps, those
patients with worse baseline visual function found to have
elevated pNF-H could be targeted with a neuroprotective
strategy [31] as pNF-H levels too correlated with loss of
RNFL and macular volumes ten years later.
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